Fuller & Thaler Asset Management Inc. Grows Stake in Laboratory Co. of America Holdings (NYSE:LH)

Fuller & Thaler Asset Management Inc. boosted its stake in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 4.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,390 shares of the medical research company's stock after acquiring an additional 1,555 shares during the quarter. Fuller & Thaler Asset Management Inc.'s holdings in Laboratory Co. of America were worth $8,804,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Graney & King LLC acquired a new stake in Laboratory Co. of America in the fourth quarter valued at about $26,000. Fortitude Family Office LLC lifted its holdings in shares of Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company's stock valued at $30,000 after buying an additional 100 shares during the period. Geneos Wealth Management Inc. boosted its stake in shares of Laboratory Co. of America by 309.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock valued at $39,000 after buying an additional 127 shares in the last quarter. Human Investing LLC acquired a new position in Laboratory Co. of America during the fourth quarter worth $39,000. Finally, Heck Capital Advisors LLC purchased a new position in Laboratory Co. of America in the fourth quarter worth $44,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the company's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the sale, the chief executive officer now directly owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Amy B. Summy sold 758 shares of the firm's stock in a transaction dated Friday, March 28th. The stock was sold at an average price of $231.67, for a total value of $175,605.86. Following the completion of the transaction, the executive vice president now owns 5,302 shares in the company, valued at approximately $1,228,314.34. This trade represents a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,258 shares of company stock valued at $3,518,177. Insiders own 0.84% of the company's stock.

Analyst Upgrades and Downgrades

LH has been the topic of a number of recent analyst reports. Truist Financial lowered their price target on shares of Laboratory Co. of America from $285.00 to $274.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. UBS Group dropped their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Barclays dropped their price objective on Laboratory Co. of America from $260.00 to $240.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Redburn Atlantic started coverage on Laboratory Co. of America in a research note on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price target for the company. Finally, Jefferies Financial Group increased their price objective on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Laboratory Co. of America presently has an average rating of "Moderate Buy" and a consensus target price of $268.77.

Laboratory Co. of America Trading Up 0.9 %

LH traded up $2.14 during trading on Monday, hitting $230.45. The company's stock had a trading volume of 983,764 shares, compared to its average volume of 633,708. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $258.59. The stock has a market cap of $19.28 billion, a PE ratio of 26.13, a PEG ratio of 1.71 and a beta of 0.99. The firm's 50 day moving average price is $234.95 and its 200-day moving average price is $235.38. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, analysts expect that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 11th. Investors of record on Thursday, May 29th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.25%. Laboratory Co. of America's payout ratio is 32.65%.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.